Clinical Trial Detail

NCT ID NCT02241720
Title Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements no
Sponsors University of Utah
Indications

esophagus adenocarcinoma

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.